Reckitt Struggles To Tame Enlarged Health Portfolio As Durex and Scholl Stumble In Q2
Executive Summary
Durex, Scholl and a number of regional OTC brands fell short of expectations in Q2 as RB reported like-for-like Health sales down by 1%. Analysts are now questioning whether the UK-based firm has expanded too fast and spread itself too thin in the global consumer health market as it struggles to get the most out of its diverse portfolio.